chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 15.0
Sex: F
Vaccine: MNQ
Symptoms: Inappropriate schedule of product administration, Medication error, No adverse event
Clinical narrative: patient received the first dose at the age of 12, and the second at 15, not at 16 years of age with no reported adverse event; patient received the first dose at the age of 12, and the second at 15, not at 16 years of age with no reported adverse event; Initial information received on 09-Jun-2022 regarding an unsolicited validnon-serious case received from a pharmacist.  This case involves a 15 years old female patient who received the first dose at the age of 12, and the second at 15, not at 16 years of age with no reported adverse event while receiving vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA].   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a 1st dose and a booster dose of 0.25 ml of suspect meningococcal a-c-y-w135 (d conj) vaccine (Drug Interval Dosage: twice; Drug Treatment Duration, form, strength, route, administration site, lot number, expiry date: not reported) for prophylactic vaccination.    On an unknown date the patient received the first dose at the age of 12, and the second at 15, not at 16 years of age with no reported adverse event (inappropriate schedule of product administration) and (Product administered to patient of inappropriate age) (latency: same day). The patient is now 22 and her school has declined the vaccine record because there is not enough time between the 2 doses. The pharmacist stated people had to be over the age of 18 to receive boosters, unless it is the COVID vaccines and boosters or the influenza vaccine.   Action taken was not applicable.  Outcome was unknown.    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 5.0
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: customer asked if pentacel given on a catchup schedule, would a 5th dose of the vaccine be needed to complete the series and if so when should patient receive the 5th dose with no reported adverse event; Initial information received on 10-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 5 years old female patient who asked if diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine [Pentacel] given on a catchup schedule, would a 5th dose of the vaccine be needed to complete the series and if so when should patient receive the 5th dose with no reported adverse event.   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Hepatitis A Vaccine (Hepatitis A) for Immunisation.  On an unknown date in 2017, the patient received a 1st dose of suspect Pentacel, On an unknown date in April 2019 received a  second dose, on an unknown date in February 2019 received third dose and on 31-May-2022 received a fourth dose of the vaccine (dose 0.5 ml, once, Lot: UJ612AAA, 28-Jan-2023 via intramuscular route at right leg strength: standard) for immunization.  On 31-May-2022 (Latency: same day) the customer asked if pentacel given on a catchup schedule, would a 5th dose of the vaccine be needed to complete the series and if so when should patient receive the 5th dose with no reported adverse event (product use issue). As per local labelling adverse event due to pentacel on a catchup schedule should be given to a patient after the age of 5.   Action taken was not applicable.  At time of reporting, the outcome was Unknown.    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 12.0
Sex: F
Vaccine: MNQ
Symptoms: Medication error, No adverse event, Product use issue
Clinical narrative: a nurse inadvertently administered MENACTRA to a patient who was supposed to receive Gardasil with no reported adverse event; had just received a dose of MENACTRA on 10Aug202, she received another dose of MENACTRA too early with no reported adverse event; Initial information received on 10-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional via call center.  This case involves a 12 years old female patient who was inadvertently administered menactra by nurse who was supposed to receive gardasil with no reported adverse event and had just received a dose of menactra on 10aug2021, she received another dose of menactra too early with no reported adverse event while receiving vaccine Meningococcal A-C-Y-W135 (D Conj) Vaccine [Menactra].  The patient's past vaccination(s) included Menactra on 10-AUG-2021. The patient's past medical history, medical treatment(s) and family history were not provided.  Concomitant medications included Hpv Vaccine Vlp Rl1 4v (Yeast) (Gardasil) for Prophylactic vaccination.  On 09-Jun-2022, the patient received a 0.5 ml dose of suspect meningococcal A-C-Y-W135 (D CONJ) vaccine lot U7208AA, expiry date: 10-Feb-2023, frequency: once unknown strength and formulation via intramuscular route in the right deltoid as immunization.  On 09-JUN-2022 the patient developed non-serious events a nurse inadvertently administered menactra to a patient who was supposed to receive gardasil with no reported adverse event (wrong product administered) and had just received a dose of menactra on 10aug2021, she received another dose of menactra too early with no reported adverse event (product use issue) latency: same day following the administration of meningococcal a-c-y-w135 (d conj) vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for both the events.  At time of reporting, the outcome was Unknown for both the events.    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.33
Sex: F
Vaccine: DTAPIPVHIB
Symptoms: Incomplete course of vaccination, No adverse event
Clinical narrative: Caller states that a nurse just gave the (DTaP-IPV component) diluent portion of the PENTACEL vaccine without adverse event; Initial information received  on 10-Jun-2022 regarding an unsolicited valid  non-serious case received from a physician.  This case involves a 4 months old female patient to whom nurse just gave the (dtap-ipv component) diluent portion of the diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine [Pentacel] vaccine without adverse event.    The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included pneumococcal vaccine conj 7v (crm197) (prevnar) for immunisation; and rotavirus vaccine live reassort oral 5v (rotateq) for immunization.  On 10-Jun-2022, the patient received a dose of 0.5 ml, total, Frequency: 1 day (once) of suspect diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine, strength = standard via intramuscular route in the right thigh for immunization liquid diluent (Lot: U6986AA, expiry: 7/22/22), lyophilized powder (lot: UJ52AA exp 7/22/22) single dose vial with diluent.   On 10-Jun-2022 the nurse just gave the (dtap-ipv component) diluent portion of the pentacel vaccine without adverse event (incomplete course of vaccination) as only the DTaP-IPV component was administered, and the lyophilized powder was missed. Caller wanted to know if dose needs to be repeated.    Action taken was not applicable. At time of reporting, the outcome was Unknown.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.33
Sex: U
Vaccine: MNQ
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: 4 month old was given MENQUADFI/administration to a child younger than indicated age range with no other reported adverse event; Initial information received on 10-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional via call center.  This case involves a 4 months old and unknown gender patient who was given menquadfi/administration to a child younger than indicated age range with no other reported adverse event while receiving vaccine Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect meningococcal a-c-y-w135 (t conj) vaccine (dose, route, strength, formulation, frequency, batch lot number and expiry date: unknown) in unknown administration site for immunization.  On an unknown date the patient developed a non-serious event 4 month old was given menquadfi/administration to a child younger than indicated age range with no other reported adverse event (product use issue) (unknown latency) following the administration of meningococcal a-c-y-w135 (t conj) vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (product use issue).  At time of reporting, the outcome was Unknown for the product use issue.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.5
Sex: M
Vaccine: HIBV
Symptoms: Medication error, No adverse event, Product preparation error
Clinical narrative: ACTHIB that was diluted with a different diluent aside from the diluent associated with the vaccine with no reported adverse event; Initial information received on 10-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 6 months old male patient to whom given HIB (PRP/T) VACCINE [ACT-HIB]  that was diluted with a different diluent aside from the diluent associated with the vaccine with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), PERTUSSIS VACCINE ACELLULAR 3-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID (PEDIARIX) for Immunisation; PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13) for Immunisation; and ROTAVIRUS VACCINE LIVE ORAL 1V (ROTARIX) for Immunisation.  On 10-Jun-2022, the patient received a  dose of suspect HIB (PRP/T) VACCINE (lot UJ604AA) via intramuscular route in the left thigh vaccine  was diluted with a different diluent aside from the diluent associated with the vaccine with no reported adverse event (product preparation error).  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event acthib that was diluted with a different diluent aside from the diluent associated with the vaccine with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 11.0
Sex: M
Vaccine: MNQ
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: 11 year old patient was administered MENACTRA which expired 4 days ago with no reported adverse event; Initial information received on 13-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves 11 year old  male patient was administered meningococcal A-C-Y-W135 (D CONJ) vaccine [Menactra] which expired 4 days ago with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (TDAP) for Immunisation.  On 13-Jun-2022, the patient received a  dose of suspect meningococcal A-C-Y-W135 (D CONJ) vaccine (lot number not reported and expiry date: 09-Jun-2022) via intramuscular route in unknown administration site.  On 13-JUN-2022 the patient was administered menactra which expired 4 days ago with no reported adverse event (expired product administered).  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event 11 year old patient was administered menactra which expired 4 days ago with no reported adverse event.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 12.0
Sex: M
Vaccine: TD
Symptoms: Medication error, No adverse event, Wrong product administered
Clinical narrative: administered Tenivac instead of Boostrix with no reported adverse event; Initial information received  on 14-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 12 years old male patient who was administered Tenivac instead of Boostrix with no reported adverse event , (suspect vaccine: DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC]) .   Concomitant medications included VARICELLA ZOSTER VACCINE (VARICELLA VACCINE) for Prophylactic vaccination; MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) (MENACTRA) for Prophylactic vaccination; HPV VACCINE (HPV VACCINE) for Prophylactic vaccination; HEPATITIS A VACCINE (HEPA [HEPATITIS A VACCINE]) for Prophylactic vaccination; and POLIO VACCINE (POLIO) for Prophylactic vaccination.  On 13-Jun-2022, the patient received a  0.5 ml dose of suspect DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT, once, ( lot: U71E9AA ; Expiry date: 30-Sep-2023)  via intramuscular route in the left deltoid for immunization.  The reported stated that they administered Tenivac instead of Boostrix to the patient  with no reported adverse event (wrong product administered) (onset and  latency: unknown)   Action taken : not applicable.  Outcome: unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  01145424:
Age: 17.0
Sex: M
Vaccine: TD
Symptoms: Medication error, No adverse event, Wrong product administered
Clinical narrative: administered Tenivac instead of Boostrix with no reported adverse event; Initial information received on 14-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 17 years old male patient who was administered Tenivac instead of Boostrix with no reported adverse event , (suspect vaccine: DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC]).   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included VARICELLA ZOSTER VACCINE (VARICELLA VACCINE); MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) (MENACTRA); HPV VACCINE (HPV VACCINE); and HEPATITIS A VACCINE (HEPATITIS A VACCINE).  On 13-Jun-2022, the patient received a  0.5 ml dose of suspect DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT, once, ( lot: U71E9AA ; Expiry date: 30-Sep-2023)  via intramuscular route in the left deltoid for immunization.  The reported stated that they administered Tenivac instead of Boostrix to the patient  with no reported adverse event (wrong product administered) (onset: 13-Jun-2022 and  latency: same day)   Action taken : not applicable.  Outcome: unknown  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments:  01145385:
Age: 1.0
Sex: M
Vaccine: DTAP
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: inadvertently administered an expired dose of Daptacel with no reported adverse event; Initial information received from on 14-Jun-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-HCP.  This case involves a 1 years old male patient who was inadvertently administered an expired dose of daptacel with no reported adverse event , for receiving  vaccine DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL].   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, HIB VACCINE CONJ (TET TOX), PERTUSSIS VACCINE ACELLULAR 5-COMPONENT, POLIO VACCINE INACT 3V (MRC 5), TETANUS VACCINE TOXOID (PENTACEL) for Prophylactic vaccination; HIB VACCINE (HIB) for Prophylactic vaccination; and MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR) for Prophylactic vaccination.  On 14-Jun-2022, the patient received a  0.5 ml dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE, once, ( lot: C5743AA ; expiry date: 06-Jun-2022)  via intramuscular route in the left vastus lateralis for immunization.  it was reported that  DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE was  inadvertently administered an expired dose of daptacel with no reported adverse event (expired product administered) (onset date: 14-Jun-2022 ; expiry date: same day)  Action taken : not applicable.  Outcome: unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.5
Sex: F
Vaccine: FLUR4
Symptoms: No adverse event, Off label use
Clinical narrative: FLUBLOK that was administered to a 6 month old with no reported adverse event; Initial information received on 14-Jun-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves a 6 month old female patient to whom  influenza quadrivalent recombinant vaccine [Flublok Qiv] was administered with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), PERTUSSIS VACCINE ACELLULAR 3-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID (PEDIARIX) for Immunisation; HIB VACCINE CONJ (OMPC) (PEDVAXHIB) for Immunisation; PNEUMOCOCCAL VACCINE (PNEUMOCOCCAL VACCINE) for Immunisation; and ROTAVIRUS VACCINE LIVE ORAL 1V (ROTARIX) for Immunisation.  On 28-Mar-2022, the patient received 0.5ml  dose of suspect  influenza quadrivalent recombinant vaccine (strength, formulation not reported)(lot QFAA2137; expiry date: 30-Jun-2022) via intramuscular route in the right thigh for Immunisation.  On 28-Mar-2022 the flublok that was administered to a 6 month old with no reported adverse event (off label use).  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event flublok that was administered to a 6 month old with no reported adverse event.
Sex: U
Vaccine: UNK
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: patient has been given expired PENTACEL with no adverse event; Initial information received on 14-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a patient of unknown gender and age who experienced patient has been given expired pentacel with no adverse event while receiving vaccine Diphtheria/Tetanus/5 Hybrid Ac Pertussis/Ipv(Vero)/Hib(Prp/T) Vaccine [Pentacel (Vero)].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect diphtheria/tetanus/5 hybrid ac pertussis/ipv(vero)/hib(prp/t) vaccine expiry date: 29-May-2022, frequency: once (dose, route, strength, formulation, batch lot number: unknown) in unknown administration site as immunization.  On an unknown date the patient developed a non-serious event patient has been given expired pentacel with no adverse event (expired product administered) (latency: same day) following the administration of diphtheria/tetanus/5 hybrid ac pertussis/ipv(vero)/hib(prp/t) vaccine.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (expired product administered).  At time of reporting, the outcome was Unknown for the event expired product administered.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.42
Sex: M
Vaccine: HIBV
Symptoms: No adverse event, Product preparation issue
Clinical narrative: ACTHIB was administered to a patient using sterile water instead of the diluent provided with no reported adverse event; Initial information was received on 14-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional via call center.   This case involves a 5 months old male patient who experienced acthib was administered to a patient using sterile water instead of the diluent provided with no reported adverse event while receiving vaccine HIB (PRP/T) VACCINE [ACT-HIB].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (DTAP) for Immunisation; PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13) for Immunisation; and POLIO VACCINE INACT 3V (VERO) (IPOL [POLIO VACCINE INACT 3V (VERO)]) for Immunisation.  On 13-Jun-2022, the patient received 0.5 ml of suspect HIB (PRP/T) vaccine (lot, expiry, formulation, and strength: unknown) via intramuscular route in left thigh for immunisation.  On 13-JUN-2022 the patient developed a non-serious acthib was administered to a patient using sterile water instead of the diluent provided with no reported adverse event (product preparation error) (latency same day) following the administration of HIB (PRP/T) VACCINE.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event acthib was administered to a patient using sterile water instead of the diluent provided with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 62.0
Sex: F
Vaccine: TD
Symptoms: Fatigue, Injection site pain, Loss of personal independence in daily activities, Pain, Pain in extremity
Clinical narrative: Time of injection much pain, next day more pain in arm. Pain and extreme fatigue continued to progress daily/weekly until by May(2 months later) pain and fatigue intolerable and unable to function in normal capacity. Now 3 months later only getting worse, intolerable and no one seems to know how to help. I cannot go on like this.
Age: 10.0
Sex: F
Vaccine: COVID19
Symptoms: Needle issue
Clinical narrative: Error: Wrong Needle Length-
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Inappropriate schedule of product administration, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Pfizer 6/22/21 EW0191 dose 2 Pfizer 7/22/21 FA7485
Age: 59.0
Sex: M
Vaccine: VARZOS
Symptoms: Chills, Diarrhoea, Immediate post-injection reaction, Injection site pain, Nausea
Clinical narrative: Nausea and diarrhea (12 hours after injection, quickly resolved) , fever, chills and  body aches (13 hours after injection, gradually improved 2-3 days after injection), pain at injection site (immediately after injection, slowly  diminishing 4 days after injection).
Age: 59.0
Sex: M
Vaccine: VARZOS
Symptoms: Pain, Pyrexia
Clinical narrative: Nausea and diarrhea (12 hours after injection, quickly resolved) , fever, chills and  body aches (13 hours after injection, gradually improved 2-3 days after injection), pain at injection site (immediately after injection, slowly  diminishing 4 days after injection).
Age: 38.0
Sex: F
Vaccine: UNK
Symptoms: Aneurysm ruptured, Angiogram cerebral abnormal, Anticoagulant therapy, Brain operation, Cerebrovascular accident
Clinical narrative: After receiving my vaccine I got your normal symptoms.  A few days later the headache came back and never went away. I didn?t think much of it until a couple of weeks later whenever it began to affect my vision. So I went to go get my eyes checked and got new glasses and new lenses. That still didn?t work. It continued to do the same thing and the headache wouldn?t go away so then I went to get my lenses changed because I thought maybe it was the lenses but it was not the lenses. My PCP then sent me for an MRI and I had a CT but those were clear. About a week and a half later I was having a really sharp pain in my head that I had never had before so I went and asked again and told him that this pain was just not normal because I?ve never had it before. Prior to the vaccine I was living my normal life seeing my doctor annually and never having any issues or problems. I went for an MRA and deep inside my brain after getting this vaccine they found an aneurysm. The symptoms I had after getting the vaccine were completely new as I had never had anything before. By December I was having Brain Surgery because my Aneurysm that this Vaccine caused began to leak into my spinal fluid and I had a stroke because of it. This Vaccine is not safe! I?m an effort to prevent blood clots because it?s been told me to by my Dr that it can cause blood clots (something I?ve NEVER ever had before)  I have to now see a Hematologist because I?ll be on blood thinners possibly for the rest of my life. I?m only 38!
Age: 38.0
Sex: F
Vaccine: UNK
Symptoms: Computerised tomogram normal, Corrective lens user, General symptom, Headache, Intracranial aneurysm
Clinical narrative: After receiving my vaccine I got your normal symptoms.  A few days later the headache came back and never went away. I didn?t think much of it until a couple of weeks later whenever it began to affect my vision. So I went to go get my eyes checked and got new glasses and new lenses. That still didn?t work. It continued to do the same thing and the headache wouldn?t go away so then I went to get my lenses changed because I thought maybe it was the lenses but it was not the lenses. My PCP then sent me for an MRI and I had a CT but those were clear. About a week and a half later I was having a really sharp pain in my head that I had never had before so I went and asked again and told him that this pain was just not normal because I?ve never had it before. Prior to the vaccine I was living my normal life seeing my doctor annually and never having any issues or problems. I went for an MRA and deep inside my brain after getting this vaccine they found an aneurysm. The symptoms I had after getting the vaccine were completely new as I had never had anything before. By December I was having Brain Surgery because my Aneurysm that this Vaccine caused began to leak into my spinal fluid and I had a stroke because of it. This Vaccine is not safe! I?m an effort to prevent blood clots because it?s been told me to by my Dr that it can cause blood clots (something I?ve NEVER ever had before)  I have to now see a Hematologist because I?ll be on blood thinners possibly for the rest of my life. I?m only 38!
Age: 38.0
Sex: F
Vaccine: UNK
Symptoms: Laboratory test, Magnetic resonance imaging normal, Visual impairment
Clinical narrative: After receiving my vaccine I got your normal symptoms.  A few days later the headache came back and never went away. I didn?t think much of it until a couple of weeks later whenever it began to affect my vision. So I went to go get my eyes checked and got new glasses and new lenses. That still didn?t work. It continued to do the same thing and the headache wouldn?t go away so then I went to get my lenses changed because I thought maybe it was the lenses but it was not the lenses. My PCP then sent me for an MRI and I had a CT but those were clear. About a week and a half later I was having a really sharp pain in my head that I had never had before so I went and asked again and told him that this pain was just not normal because I?ve never had it before. Prior to the vaccine I was living my normal life seeing my doctor annually and never having any issues or problems. I went for an MRA and deep inside my brain after getting this vaccine they found an aneurysm. The symptoms I had after getting the vaccine were completely new as I had never had anything before. By December I was having Brain Surgery because my Aneurysm that this Vaccine caused began to leak into my spinal fluid and I had a stroke because of it. This Vaccine is not safe! I?m an effort to prevent blood clots because it?s been told me to by my Dr that it can cause blood clots (something I?ve NEVER ever had before)  I have to now see a Hematologist because I?ll be on blood thinners possibly for the rest of my life. I?m only 38!
Age: 1.17
Sex: M
Vaccine: DTAPHEPBIP, FLUC4, HEPA, HIBV, MMR, PNC13, VARCEL
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Client too young for Flucelvax.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Hypovolaemia, Syncope
Clinical narrative: Explosive diarrhea, volume depletion and orthostatic syncope requiring EMS, emergency room visit and 2 liters of IV fluids
Age: 0.17
Sex: M
Vaccine: HIBV
Symptoms: No adverse event, Product administration error, Product preparation issue
Clinical narrative: Package insert states .85 diluent in vial and to draw up .6 to reconstitute. All the diluent was drawn up for reconstitution. Manufacture notified of administration error and recommended to repeat dose.  From 2017 to present there have been 9946 doses administered in the local health units. At the present time Department of Health is working on notifying all children under the age of 5 years that received a dose with the full amount of diluent for revaccination.   The error was identified by the Immunization Nurse as she was updating policy. No adverse events have been identified.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Anticoagulant therapy, Atrial fibrillation, COVID-19, Condition aggravated
Clinical narrative: Discharge Provider: MD Primary Care Provider: DO Admission Date: 6/6/2022 Discharge Date: Jun 15, 2022  PRESENTING PROBLEM: Acute on chronic respiratory failure with hypoxia and hypercapnia COVID-19 virus infection   HOSPITAL COURSE: Patient is a 77-year-old man who is admitted to the hospital with acute on chronic hypercapnic and hypoxic respiratory failure secondary to COVID-19 infection.  I also suspect he had healthcare associated pneumonia after being intubated initially for 2 days.  Patient was treated with 5 days of cefepime and only 2 days of vancomycin as his MRSA screen is negative.  He was treated with remdesivir and completed a 5 day course.  He also was noted to have atrial fibrillation with RVR which was new.  He was initially placed on therapeutic Lovenox.  At time of discharge the family and the patient wanted to switch to Coumadin.  He was prescribed 5 mg daily and has follow-up with his primary care provider in 2 days.  He was also started on Toprol 50 mg daily for rate control.  At baseline, the patient wears 3 L nasal cannula of oxygen.  In the hospital here is requiring 3 L at rest and 6 L with any activity.  He was given a prescription for a new oxygen concentrator.  Patient had a overnight pulse oximetry study which qualified him for BiPAP use.  This was prescribed at time of discharge.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Endotracheal intubation, Hypercapnia, Hypoxia, Pneumonia, Positive airway pressure therapy
Clinical narrative: Discharge Provider: MD Primary Care Provider: DO Admission Date: 6/6/2022 Discharge Date: Jun 15, 2022  PRESENTING PROBLEM: Acute on chronic respiratory failure with hypoxia and hypercapnia COVID-19 virus infection   HOSPITAL COURSE: Patient is a 77-year-old man who is admitted to the hospital with acute on chronic hypercapnic and hypoxic respiratory failure secondary to COVID-19 infection.  I also suspect he had healthcare associated pneumonia after being intubated initially for 2 days.  Patient was treated with 5 days of cefepime and only 2 days of vancomycin as his MRSA screen is negative.  He was treated with remdesivir and completed a 5 day course.  He also was noted to have atrial fibrillation with RVR which was new.  He was initially placed on therapeutic Lovenox.  At time of discharge the family and the patient wanted to switch to Coumadin.  He was prescribed 5 mg daily and has follow-up with his primary care provider in 2 days.  He was also started on Toprol 50 mg daily for rate control.  At baseline, the patient wears 3 L nasal cannula of oxygen.  In the hospital here is requiring 3 L at rest and 6 L with any activity.  He was given a prescription for a new oxygen concentrator.  Patient had a overnight pulse oximetry study which qualified him for BiPAP use.  This was prescribed at time of discharge.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Staphylococcus test negative
Clinical narrative: Discharge Provider: MD Primary Care Provider: DO Admission Date: 6/6/2022 Discharge Date: Jun 15, 2022  PRESENTING PROBLEM: Acute on chronic respiratory failure with hypoxia and hypercapnia COVID-19 virus infection   HOSPITAL COURSE: Patient is a 77-year-old man who is admitted to the hospital with acute on chronic hypercapnic and hypoxic respiratory failure secondary to COVID-19 infection.  I also suspect he had healthcare associated pneumonia after being intubated initially for 2 days.  Patient was treated with 5 days of cefepime and only 2 days of vancomycin as his MRSA screen is negative.  He was treated with remdesivir and completed a 5 day course.  He also was noted to have atrial fibrillation with RVR which was new.  He was initially placed on therapeutic Lovenox.  At time of discharge the family and the patient wanted to switch to Coumadin.  He was prescribed 5 mg daily and has follow-up with his primary care provider in 2 days.  He was also started on Toprol 50 mg daily for rate control.  At baseline, the patient wears 3 L nasal cannula of oxygen.  In the hospital here is requiring 3 L at rest and 6 L with any activity.  He was given a prescription for a new oxygen concentrator.  Patient had a overnight pulse oximetry study which qualified him for BiPAP use.  This was prescribed at time of discharge.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Fatigue, Headache, Malaise, Pain
Clinical narrative: Malaise, headache, generalized aching beginning on 5/20 Continual achiness and fatigue throughout this time
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain, Pyrexia
Clinical narrative: Chills, fever, body aches, exhaustion, headache
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: While onboarding a new team member who was 17 years old Moderna was administered when she should have received Pfizer.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Dysphagia, Fatigue, Feeling abnormal
Clinical narrative: She got her vaccine, the first day she was very tired.  When she woke up in the morning she had chills, which went into a fever and aches.  Around 11:00 PM she got up to use the bathroom and her legs went out from under her.  She wound up on the floor and she could not get up.  She had a temp of 101.9.  Day #2 she felt that her legs were weak, she started using her cane, moving carefully and had a fever of 100.8, chills, aches and feeling crappy, and sort of brain fog.  The third day, the fever went away but the arm pain increased and she also had a rash (COVID arm).  Today she is just really tired, and having trouble swallowing, which is brand new, but also does not have much of an appetite.  She has been taking extra Tylenol.  She has an appointment with her PCP on Wednesday, (already scheduled).  The first vaccine she didn't have any reactions until day #9 and then had a rash from shoulder to elbow (has pictures).  The second vaccine she had a fever of 102.1 and then 100.9 the 2nd day and then she was OK, just tired.    She generally is a healthy individual, just in a lot of pain.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Mobility decreased, Muscular weakness, Pain, Pain in extremity, Pyrexia
Clinical narrative: She got her vaccine, the first day she was very tired.  When she woke up in the morning she had chills, which went into a fever and aches.  Around 11:00 PM she got up to use the bathroom and her legs went out from under her.  She wound up on the floor and she could not get up.  She had a temp of 101.9.  Day #2 she felt that her legs were weak, she started using her cane, moving carefully and had a fever of 100.8, chills, aches and feeling crappy, and sort of brain fog.  The third day, the fever went away but the arm pain increased and she also had a rash (COVID arm).  Today she is just really tired, and having trouble swallowing, which is brand new, but also does not have much of an appetite.  She has been taking extra Tylenol.  She has an appointment with her PCP on Wednesday, (already scheduled).  The first vaccine she didn't have any reactions until day #9 and then had a rash from shoulder to elbow (has pictures).  The second vaccine she had a fever of 102.1 and then 100.9 the 2nd day and then she was OK, just tired.    She generally is a healthy individual, just in a lot of pain.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Walking aid user
Clinical narrative: She got her vaccine, the first day she was very tired.  When she woke up in the morning she had chills, which went into a fever and aches.  Around 11:00 PM she got up to use the bathroom and her legs went out from under her.  She wound up on the floor and she could not get up.  She had a temp of 101.9.  Day #2 she felt that her legs were weak, she started using her cane, moving carefully and had a fever of 100.8, chills, aches and feeling crappy, and sort of brain fog.  The third day, the fever went away but the arm pain increased and she also had a rash (COVID arm).  Today she is just really tired, and having trouble swallowing, which is brand new, but also does not have much of an appetite.  She has been taking extra Tylenol.  She has an appointment with her PCP on Wednesday, (already scheduled).  The first vaccine she didn't have any reactions until day #9 and then had a rash from shoulder to elbow (has pictures).  The second vaccine she had a fever of 102.1 and then 100.9 the 2nd day and then she was OK, just tired.    She generally is a healthy individual, just in a lot of pain.
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cardiac arrest, Dyspnoea, Intensive care, SARS-CoV-2 test positive
Clinical narrative: Hospitalization for shortness of breath and cardiac arrest, positive for COVID on dates 5/15/2022- 5/27/2022. Treated with dexamethasone, methylprednisolone, zinc, and other IV drips in the ICU for organ support.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: The facility was not aware of prior doses and a full 3rd dose was given thinking that this was the patient's 1st dose.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: The facility was not aware of prior doses and thought the patient was due for a 2nd dose but it was their 4th full dose.
Age: 78.0
Sex: M
Vaccine: FLU4
Symptoms: Extra dose administered
Clinical narrative: It appears that the patient received a high-dose flu vaccine on 9/30/21 and then a regular flu vaccine on 11/17/21.
Age: 78.0
Sex: F
Vaccine: VARZOS
Symptoms: Headache, Injection site pain, Malaise, Pain
Clinical narrative: Achiness, headache, pain at site of shot, overall malaise
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Chronic obstructive pulmonary disease, Condition aggravated, Hypoxia, SARS-CoV-2 test positive
Clinical narrative: Hospitalization on dates 5/12/2022- 5/21/2022 for hypoxemia likely secondary to COPD exacerbation, positive for COVID 5/13/2022 . Treated with dexamethasone, methylprednisolone, prednisone
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Oropharyngeal discomfort, Paraesthesia oral
Clinical narrative: Patient had a potential allergic reaction to the vaccine. Patient experienced chest tightness, dizziness, tongue tingling, throat felt full and funny 2 hours after receiving the booster dose. she took 50mg of Benadryl.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: hospitalization of fully vaccinated coivd positive pt
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: The patient received a 2nd booster dose. Patient did not recall having a prior booster, but the database reports that the patient had one on 11/9/21.
Age: 14.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site swelling, Pain in extremity, Tenderness
Clinical narrative: swollen armpit nearest the injection site, pain/tenderness of injected arm
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19
Clinical narrative: Hospitalization for COVID-19 on dates 5/12/2022- 5/17/2022. Treated with dexamethasone, zinc, cholecalciferol, ascorbic acid
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Malaise, Vertigo
Clinical narrative: Employee sent an email on 06/16/2022 @ 1126 complaining of "feeling very dizzy, room spinning, like I had a of alcohol kind of spinning, It is making me feel like I'm going to be sick" Employee was called right away.  She was able to speak in full sentences without any difficulty. She did not complain of shortness of breath or any other adverse effects.  She wanted to know who long the dizziness will last.  I explained that one of the adverse effect of Janssen was dizziness, no information was given about the duration of the dizziness. I offered to call an ambulance if she is not well, but she declined.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Fatigue, Headache, Neck pain, Pain in extremity
Clinical narrative: Sore arm, armpit, neck, fatigue, and headache
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Acute respiratory failure, COVID-19, Chronic obstructive pulmonary disease, Condition aggravated, Respiratory failure
Clinical narrative: Hospitalization for acute on chronic hypoxic and hypercapnic respiratory failure secondary to COPD exacerbation and COVID-19 on dates 5/11/2022- 5/16/2022.  Treated with ascorbic acid, baricitinib, cholecalciferol, dexamethasone, remdesivir, and zinc.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: The patient received a 2nd booster dose. The patient did not recall having a prior booster dose, but the database reports that the patient had one on 11/9/2021.
Age: 78.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Syncope
Clinical narrative: Hospitalization for syncope and COVID-19 on dates 5/6/2022- 5/8/2022. Treated with cholecalciferol, ascorbic acid, zinc.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient received a 3rd dose of Moderna from a vial that had been expired for 11 days. The patient stated that they did similar to prior doses where they felt an immune response.